Emerging oral antiplatelet receptor inhibitors

Introduction Aspirin remains the cornerstone of antiplatelet therapy for the prevention and treatment of coronary, cerebral, and peripheral artery disease. 1 It has several attractive properties that have contributed to its success, including (i) once-daily oral administration, (ii) the ability to permanently inactivate a platelet protein (cyclooxygenase-1) that cannot be resynthesized during the life of the platelet, (iii) lack of requirement …